In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
The in vitro activity of the peptide IB-367, alone or combined with either fluconazole (FLU) or amphotericin B (AMB), was investigated against 25 Candida isolates belonging to five species. IB-367 minimum inhibitory concentrations (MICs) ranged from 2.0 to 32 microg/ml and it was active against both FLU-susceptible and - resistant isolates. A rapid fungicidal activity was observed. Synergism was documented in 41.6% and 44% of IB-367/FLU and IB-367/AMB interactions, respectively. Antagonism was never observed. The broad antifungal activity and the positive interactions with AMB and FLU suggest that IB-367 represents a promising candidate against infections due to Candida spp.
Barchiesi
F
F
Institute of Infectious Diseases and Public Health, Università Politecnica delle Marche, Ancona, Italy.
Giacometti
A
A
Cirioni
O
O
Arzeni
D
D
Kamysz
W
W
Silvestri
C
C
Licci
A
A
Marigliano
A
A
Della Vittoria
A
A
Nadolski
P
P
Łukasiak
J
J
Scalise
G
G
D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy; D025141:Drug Resistance, Fungal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology*
D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; D010455:Peptides; D000666:Amphotericin B; D015725:Fluconazole; C119872:antimicrobial peptide IB-367